Exploring the mechanism of Yi Qi Huo Xue compound prescription in treating chronic heart failure based on integrated network pharmacology and transcriptomics
Frontiers in Cardiovascular Medicine · 23.03.2026 · 13
DOI: 10.3389/fcvm.2026.1738535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 23.03.2026. Verfasst von Jiadan Liao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Chronic heart failure (CHF) represents a major global health burden characterized by complex pathologies. The Yi Qi Huo Xue compound prescription (YQHXCP) has demonstrated significant clinical efficacy in alleviating heart failure symptoms; however, its precise molecular mechanisms remain obscure.
Objective
This study aims to elucidate the core targets and biological pathways of YQHXCP in treating CHF through an integrated approach combining network pharmacology with transcriptomic validation.
Methods
A rat model of heart failure was established, and transcriptomic data were acquired via RNA sequencing. Concurrently, putative targets of YQHXCP were retrieved from the TCMSP and SwissTargetPrediction databases. Key targets were identified by intersecting differentially expressed genes (DEGs) from the animal model with predicted drug targets. Subsequently, functional enrichment analysis, gene-gene interaction (GGI) network construction, and molecular docking were employed to decipher the underlying mechanisms, followed by in vivo validation using RT-qPCR.
Results
Three pivotal target genes were identified: Top2a, Cdk1, and E2f2. Enrichment analysis revealed that YQHXCP primarily modulates mitochondrial protein complexes, ribosomal subunit assembly, and cell cycle checkpoints. Molecular docking demonstrated strong binding affinity between the active ingredient quercetin and both Cdk1 and E2f2 proteins. RT-qPCR confirmed that YQHXCP significantly reversed the downregulation of Cdk1 and E2f2 expression in the myocardial tissue of CHF rats.
Conclusion
YQHXCP may exert its anti-CHF effects by targeting Cdk1 and E2f2 to regulate mitochondrial function and cell cycle homeostasis. These findings provide novel insights into the multi-target therapeutic mechanisms of traditional Chinese medicine formulations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Tuberculosis, Hangzhou Red Cross Hospital, Hangzhou, China.
- Department of Cardiology, Longquan People's Hospital, Lishui, China.
- Department of Cardiology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
Zitieren
APA
Liao, J., Wang, P., Wu, Z., Cui, J., Shen, P., & Chen, X. (2026). Exploring the mechanism of Yi Qi Huo Xue compound prescription in treating chronic heart failure based on integrated network pharmacology and transcriptomics. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1738535
Vancouver
Liao J, Wang P, Wu Z, Cui J, Shen P, Chen X. Exploring the mechanism of Yi Qi Huo Xue compound prescription in treating chronic heart failure based on integrated network pharmacology and transcriptomics. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1738535
BibTeX
@article{Liao2026,
author = {Liao, Jiadan and Wang, Pengcheng and Wu, Zuoyue and Cui, Juan and Shen, Peiyun and Chen, Xufeng},
title = {Exploring the mechanism of Yi Qi Huo Xue compound prescription in treating chronic heart failure based on integrated network pharmacology and transcriptomics},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1738535}
}
EUVIMED